ArticleInternational journal of nanomedicine2025
A Strategy to Design Non-Symmetric Compound by Modifying the End-Group Functional Atoms for Photothermal and Photodynamic Therapy of Tumor.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The exploration of non-symmetric compound for combined photothermal therapy (PTT) and photodynamic therapy (PDT) in tumor treatment remains largely unexplored. Methods: Through a molecular design strategy, a series of compound (Y-4Cl, Y-2Br, and Y-2Cl-Br) with fused - ring benzothiazole - pyrrole - thiophene - indenone constructure were synthesized to explore its phototherapy properties, to investigate their phototherapeutic properties, respectively. The non-symmetric compound Y-2Cl-Br was further formulated into nanoparticles (NPs) for detailed evaluation. Results: The non-symmetric organic compound Y-2Cl-Br demonstrated a high molar extinction coefficient (ε) of 3.0 × 10 Conclusion: Both in vitro and in vivo studies confirmed that Y-2Cl-Br NPs are highly effective in PTT and PDT for tumor treatment, with minimal adverse effects. This work provides valuable insights into the design and application of non-symmetric organic compound photosensitizers (PSs) in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.